Kestra Medical Reports 63% Revenue Growth Amid VA and Medicaid Expansion

Kestra Medical (KMTS) is rapidly transitioning from an emerging medical technology player to a formidable challenger in the wearable cardioverter defibrillator (WCD) market. The company’s Q3 2026 financial results highlight a period of aggressive commercial scaling, characterized by a 63% year-over-year revenue surge to $24.6 million. This growth was primarily fueled by a 58% increase in prescriptions for its flagship Assure system, which surpassed 5,400 units during the quarter. The results suggest that Kestra’s strategy of clinical differentiation and sales force expansion is successfully eroding the market share of established incumbents like Zoll Medical.

A standout metric in the report is the ninth consecutive quarter of sequential gross margin expansion, which reached 52.6%. This is a significant milestone for a mid-stage medical device company, as it demonstrates that Kestra is effectively managing its manufacturing costs and service delivery even as it scales. The margin improvement was bolstered by a strategic shift in the company’s billing mix; in-network billing now accounts for over 80% of revenue, up from 70% at the time of its initial public offering. This shift not only supports higher revenue per patient fit but also streamlines the revenue cycle, reducing the administrative friction that often plagues high-cost wearable devices.

“

Kestra reported a GAAP net loss of $34.2 million for the quarter, a significant increase from the $21.8 million loss recorded in the prior-year period.

Operationally, Kestra is doubling down on its commercial footprint. The company ended the calendar year with approximately 100 active sales territories and is on track to reach 130 by the end of its fiscal year in April. This expansion is targeted at high-volume geographies where payer coverage is most robust. The recent addition to the U.S. Department of Veterans Affairs (VA) Federal Supply Schedule is perhaps the most significant strategic win of the quarter. By gaining access to VA hospitals nationwide, Kestra has unlocked a massive, centralized patient population that provides a stable and high-volume channel for the Assure system, likely serving as a major growth catalyst for the 2027 fiscal year.

Furthermore, Kestra’s success in securing managed Medicaid provider status in Florida, including agreements with two of the state's four largest plans, indicates a broadening of the addressable market beyond traditional private insurance and Medicare. This move into the Medicaid space is critical for capturing a more diverse patient demographic and ensuring that the Assure system becomes a standard of care across all socioeconomic segments. CEO Brian Webster and CFO Vaseem Mahboob emphasized that these payer wins are essential for maintaining the momentum of the Assure system's adoption curve.